CD8A and familial pancreatic carcinoma: Nomi et al., investigated the combination of pidilizumab and gemcitabine for resected pancreatic cancer and pembrolizumab and FOLFIRINOX for advanced GI cancer and found in vivo an increase in tumour infiltration of CD8+ T cells and a complete response (Nomi et al. 2007).